Atossa Therapeutics
ATOS
14 hedge funds and large institutions have $765K invested in Atossa Therapeutics in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.56% less ownership
Funds ownership: 0.92% → 0.36% (-0.56%)
4% less capital invested
Capital invested by funds: $798K → $765K (-$32.6K)
22% less funds holding
Funds holding: 18 → 14 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIP
Ahrens Investment Partners
Lafayette,
Louisiana
|
+$194K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.4K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$50.9K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$35K |
| 5 |
Morgan Stanley
New York
|
+$2.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$513K |
| 2 |
VF
Virtu Financial
New York
|
-$65.2K |
| 3 |
Barclays
London,
United Kingdom
|
-$48.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$35K |
| 5 |
Jane Street
New York
|
-$23K |
ATOS Hedge Fund Activity: Q1 2019 in Review
14 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2019, worth a combined $765K — down 4.1% from $798K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATOS and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Ahrens Investment Partners, opening a new position worth an estimated $194K. The largest seller was Sabby Management, exiting entirely with an estimated $513K sold.
- 14 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2019, down from 18 in Q4 2018.
- Funds reported $765K of Atossa Therapeutics stock for Q1 2019, down 4.1% quarter-over-quarter.
- 3 funds opened new Atossa Therapeutics positions in Q1 2019 and 7 closed out, a net change of -4 holders.
- The largest Atossa Therapeutics buyer in Q1 2019 was Ahrens Investment Partners, an estimated $194K added.
- The largest Atossa Therapeutics seller in Q1 2019 was Sabby Management, an estimated $513K sold.
Based on aggregated 13F filings for Q1 2019.